Allergan, Esprit, Orthovita deal

AGN completed the previously announced acquisition of Esprit for $370 million in cash (see BioCentury, Sept. 24). AGN expects to launch Esprit's Sanctura XR in the U.S. to treat incontinence in 1Q08. Esprit received U.S. rights to the once-daily formulation of Sanctura trospium from Indevus Pharmaceuticals Inc. (IDEV, Lexington, Mass). ...